MRKR News and Press, Marker Therapeutics Inc. From 03/17/22

Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinica...

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, ...

Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candida...

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, toda...

AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Its technology has similarities and differences with a number of other companies, discussed here. ALVR presents an interesting approach to an unmet medical need. For further de...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It’s time to dive into another day of investing with the biggest pre-market stock movers for Thursday! Source: f11photo/Shutterstock.com Moving stocks this morning are FDA updates, merge...

HOUSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, t...

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors PR Newswire HOUSTON , Dec. 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the developm...

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting Researchers from Baylor College of Medicine to review results from STELLA study in oral ...

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipated in Q1 2022 Company to host year-end conference c...